Send us Fan Mail What if you are a doctor and diagnosed with amyloidosis, and now you’re a patient? In this episode we’ll be talking with Dr. Charles Schulman, a general cardiologist. He was on the staff at Beth Israel Deaconess Medical Center for over 53 years, until he retired in early 2024. Back in 2020 he was diagnosed with Wild-Type Transthyretin Amyloidosis with cardiomyopathy - or ATTRwt-CM. It’s an interesting situation to be in, with lots of questions to understand how being a doctor impacts your experience as a patient and vice versa. For an overview of amyloidosis, please see episode 2 (for clinicians) or episode 3 (for patients).
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00Hi everyone. Welcome to the All Things Amyloid Podcast, where we feature patients, caregivers, and clinicians who discuss amyloidosis, a rare and incurable disease. Amyloidosis occurs when the body builds up abnormal amounts of misfolded amyloid protein, which can lead to serious and life-threatening outcomes. I'm your host, McKenzie, an amyloidosis patient and founder of Mackenzie's Mission. Our goal for this podcast is to raise awareness and share firsthand what it's like to live with this disease, to care for those affected by it, and to treat it.
SPEAKER_00We hope this leads to earlier diagnosis and start-of-treatment, which will improve patient lives. What if you're a doctor and diagnosed with amyloidosis, and now you're the patient? In this episode, we'll be talking with Dr. Charles Shulman, a cardiologist. He was on staff at Beth Israel Deacon S Medical Center for over 53 years until he retired in early 2024. Back in 2020, he was diagnosed with wild type transthyretin amyloidosis with cardiomyopathy.
SPEAKER_00It's an interesting situation to be in with lots of questions to understand how a doctor impacts your experience as a patient, and vice versa. Charles, welcome to the podcast. It's so great to have you with us today.
SPEAKER_04Oh, thank you, Mackenzie. It's great to be here.
SPEAKER_00What a fascinating story, and I'm sure one that our listeners will find very interesting. Perhaps we start with while you are a practicing cardiologist and you began to first develop symptoms.
SPEAKER_04But the right, my right hand was much worse than my left hand. And uh it progressed to the point where it actually became painful. Um I was unable, uh, for example, uh while working in the clinic, uh, unable to use a computer mouse for more than 10 or 15 minutes at a time uh because my hand would get numb. So I consulted with uh the hand surgeon uh uh uh who uh uh offered me either an injection uh or curative surgery.
SPEAKER_04Uh she re she re she advised me to just have the surgery and I agreed. I didn't have I didn't have any other symptoms at that time. I was fully active, I was practicing. Um uh I was on a reduced schedule anyway. Uh so I was I had two clinic days, but they were full days, you know. Uh 830, 830 to 5. Um, and I was seeing patients and I was teaching.
SPEAKER_04Um so the activities themselves uh weren't impacted, but my documentation was.
SPEAKER_00Certainly suffered a bit. So as you were starting to deal with these new symptoms that were were cropping up, were you using your clinician hat, so to speak, at all, to try to think about what may be going on?
SPEAKER_04Uh well, I I mean it was uh pretty obvious to me uh uh that I had carpal tunnel syndrome.
SPEAKER_02Sure.
SPEAKER_04Um, and uh and that it needed and that it needed you know it needed something. Um in terms of of uh uh the the biopsy itself, it was uh I saw the surgeon in February of 2020. And uh surge scheduled surgery was delayed by the pandemic until June. So the delay in my diagnosis was really not because anybody overlooked it, you know, it because uh nobody considered it, or because uh uh people didn't know or anything like that.
SPEAKER_04The situation that is that is the case for uh uh many of our patients, as they explained to us, but um uh it was delayed by the pandemic. Sure. And then at the time, and then uh around the time, I think it was just before the biopsy, as a matter of fact, I developed paroxysmal atriofibrillation. Um so I consulted with uh the uh atriofibrillation guru at the Beth Israel Deaconis Medical Center and started on Eloquis.
SPEAKER_00We just want to go back because I think that's really interesting. You mentioned that you had the carpal tunnel release surgery, you had you asked for a biopsy, but take us back to when, maybe how you realized that that was something that you needed to ask for or um well, there had been an article uh by uh uh the group at the Cleveland Clinic, uh, which was published two years prior to that in uh the Journal of the American College of Cardiology, which I read on a regular basis, um uh where they took a hundred people uh uh who underwent carpal tunnel surgery with no uh other clinical symptoms and did biopsies on them and found out that 10% of them were positive.
SPEAKER_04Knowing that, I asked the surgeon to please do a biopsy. She did the biopsy, the biopsy was positive for uh a conga red stain, which is the uh uh typical uh positivity that uh uh shows that you have amyloid or that you have amyloid.
SPEAKER_00Yeah, so it's so it's kind of interesting that I guess if you hadn't had the medical training and the education that you do, you wouldn't have thought to ask for the biopsy.
SPEAKER_01I wouldn't have known it.
SPEAKER_00Yeah, so would it would would the surgeon have done it instinctually? Would they have even known? Maybe you wouldn't even know you have amyloidosis until many years later.
SPEAKER_04Uh that's that's correct. That's all correct.
SPEAKER_00Yeah.
SPEAKER_04So I'm fortunate that way. Mm-hmm. Um, because uh uh uh it was possible to make the diagnosis uh uh at an early stage.
SPEAKER_00Yeah. No, I'm just curious. You found the you found the article about the carpal tunnel release surgery, but did you you're obviously a cardiologist, and I would presume that you spend the majority of your time reading articles that surround your specific field. So how did you come across the carpal tunnel release and the amyloid? Were you seeing amyloid in your clinic at that time? Was it something that people were talking about? Or did you just stumble upon this article and think, man, this this could pertain to me?
SPEAKER_04Uh number two. Interesting. Number number two. I didn't think about amyloidosis at all before. Interesting. Interesting. And people, people in the no, people, yeah, you know, I was at the time, I was working in a general medical clinic. Uh the Beth Israel Deaconist Medical Center has a clinic in Chelsea, Mass, um uh uh, which is uh uh 20 minutes away from the main campus on the on the on the other side of the Boston Harbor.
SPEAKER_04Yeah. Um so uh but nobody nobody thought about it at all.
SPEAKER_00Interesting. I mean it I can certainly understand that. So now kind of shifting gears, you've gotten, I presume, the results from the biopsy. You found out that it stained positive for Congo Red, that you very well could have amyloidosis. And talk about that moment. How did you feel as a doctor realizing that you have now just become a patient with a a very serious disease?
SPEAKER_04Um well, there were two kinds of reactions that I had at the time. As a as a physician, I you know, I reacted by saying, well, okay, we have a diagnosis. What's the next step in terms of uh you know diagnostic testing? Um as a patient, my first reaction was, oh shit.
SPEAKER_04Um but um you know finding out finding out that you have something uh that's unknown, uh that you have no idea uh what what's gonna happen to your life as a result of this. Um I'm not uh I I wouldn't use the word devastating uh because because I never reacted to it that way. But certainly is it has carries the the uh the implication of a life change.
SPEAKER_04Sure. Um so uh as a patient, just like every other patient, I became, you know, you become somewhat anxious about it.
SPEAKER_00Yeah. So then I presume you proceeded with more testing and so take us from there.
SPEAKER_04Uh well, I had an echo, which surprised me in that my show that I I had left ventricular hypertrophy, which I of course I never knew before. I had no reason to have an echo. I had a cardiac MR, which is not a fun test to have incident. Um uh and then uh uh you know the workup goes that you have once once the the the uh cardiac MR was suggestive of an infiltrative cardiomyopathy, the next step is to do a serum protein electrophrez.
SPEAKER_04Uh I did not have light chains and therefore had a pyrophosphate scan. That test was much easier to take than the cardiac MR. You know, and so the pyrophosphate scan was very positive. Uh genetic testing was done, uh, which was negative, and so the diagnosis of wild type uh uh cardiac ATTR amyloidosis was made. Sure. At that time, uh the only treatment that was really approved for that was Defamatous.
SPEAKER_04And so since September 1, it's my four-year anniversary actually, uh uh since September 1 of 2020, I've been taking Defamatous every day.
SPEAKER_00So, how do you think being a doctor impacted your behavior and your mindset as being a patient? So, how might you be different from other patients who aren't physicians who don't have the medical training that you do? Um, that you, you know, compared to the them that you see every day?
SPEAKER_04Well, uh a couple of things. Uh as a physician, I'm able to read the medical literature and access uh to the medical to the medical literature. That has pros and cons. The pros are that you can you can learn about things in in a scientific and unbiased way. The cons are that you know the uh uh Kaplan Meyer curves of survival are sitting there staring at you in the face.
SPEAKER_04Right? And so, you know, you know what median survival is, or you know, and so I I reread the attract study, that study uh of uh defamidus uh that proved that it was effective and uh for which the FDA gave uh the drug approval. Um, I reread it because I wanted to see where in the spectrum of patients that they tested, I was.
SPEAKER_04Interesting. See, so it it was somewhat relieving for me to know that I was on the milder end of things, that most of the patients in that study uh had had uh already had heart failure symptoms. Uh and so the survival is is, you know, I thought I was on the better end of the survival. Sure. Well, in addition to in addition to that, right, I'm in my I'm in my mid-80s.
SPEAKER_04And uh there are many competing uh uh comorbidities that uh that affect people in the in in the and you know uh affect octogenarians and nonogenarians, sure, uh besides whatever their main bio diagnosis is. So there are competing forms of you know causes of death. Put it that way. Um uh so you never you never know.
SPEAKER_02Yeah.
SPEAKER_04Um uh subsequently I came to learn I I think from the amyloidosis center group at uh uh in London that uh people with with uh that I resemble, let's put it that way, in terms of uh level of biomarkers um uh uh lived uh uh and treated lived uh uh their survival was uh not far defined from um uh survival without the diagnosis.
SPEAKER_04So that was encouraging. That's you know, that's as a that's you know, that's as a physician.
SPEAKER_01Yeah.
SPEAKER_04You know, but as a patient, um I'm no different than anybody else.
SPEAKER_02Yeah.
SPEAKER_04Uh I'm I become anxious uh when there's a an upcoming test. Of course. Uh I think you're you're probably more familiar with that than I am.
SPEAKER_00I can certainly empathize with you.
SPEAKER_04Um uh you know, uh the approach. I never I never thought about that before. As the as the test approaches, you become very uh anxious in terms of is this going to change my life?
SPEAKER_02Yeah.
SPEAKER_04You know, and then when the test is comes out okay, then there's a great sigh of relief. I have to take medicine. I take uh, I don't know, a dozen, a dozen pills a day and uh various uh medications. Um I have to remember to take them. I have to remember to be sure to have the prescriptions refilled, um uh just like everybody else.
SPEAKER_00Yeah. So tell me a little bit about, I mean, I'm curious to know, you were obviously a Beth Israel at the time, even if you were kind of reduced hours, but you were still a Beth Israel, and and talk about how that may have provided a pro in terms of being a physician, maybe access to resources or things that patients who don't aren't a physician or don't work in a medical system might not access.
SPEAKER_04Well, um uh I feel uh all of my medical care has been at the been at the real. Um so I mean, you know, I had cataract surgery, for example, that has nothing to do with this. But um uh and I have an appointment on Friday to see the ophthalmologist. But um uh I feel very comfortable uh there. And that's uh that's a that's a definite pro. People people know, you know, people know who I am.
SPEAKER_04Okay. I'm I'm you know, I've been around so long that uh uh you know some of the residents will say that they remember you know, some of the some of the attendings will say that they remember that that they interacted, they took one of my classes uh when they were a resident. Uh so that feels that's that's a good feel, that's a good feeling.
SPEAKER_02Sure.
SPEAKER_04Um you know, and and I I'm able to advocate for myself. That's that's a big thing for you know that that a lot of people aren't so good at.
SPEAKER_02Yeah.
SPEAKER_04And don't know that they have to, you know, stand up for themselves. I mean, I put it stand up for yourself, but really it's advocating for yourself. Yeah. People are are no are not aware that they're they're able to, for one thing. Yeah, that's a great point. Oh, the doctor says, you know, this, and they say, yes, sir, instead of instead of saying, Would you explain that to me? Yeah. Or you know, tell me, tell me your line of thinking.
SPEAKER_04Why are you thinking that? Why do you think that what are the options? Um, you know, I'm fully aware of uh being able to advocate for myself.
SPEAKER_00Yeah. Yeah, I think you know, having medical training allows you to understand that advocating for yourself as a patient is okay, right? I think a lot of patients who don't have medical training maybe feel that inferior is not the right word, but they're afraid. They're afraid, and I think they're afraid to come off as rude or kind of challenge uh a doctor's decision making or line of thought when they themselves don't have any medical training.
SPEAKER_00They don't have the confidence necessarily to ask questions and and ask for those explanations, like you said, because you don't want to come off as rude. You understand that your knowledge is far limited in comparison to the to the person sitting in front of you. And but I think it's really important for patients to understand, just like you said, that it is important and it is okay to advocate for yourself and and be a part of that decision-making process when it comes to diagnosis and treatment and and all the things that come along with having a a disease.
SPEAKER_04Well, uh for uh for a number of years, uh we're as as physicians, we're now uh much more into what's called patient-centered care and and uh shared decision making. Sure. So so there's there are uh institutional um uh institutional push, I'll use that word, to uh to involve uh the patient, you know.
SPEAKER_04Um and and you get you know very from patients you get various uh kinds of responses. You know, you know uh one type of response is whatever you say, doctor, I'll do. Another one is I don't know, uh I don't know the difference. You know, what is the difference? Uh and uh the other one is I don't want to do that. Yeah that's that's you know that's not important to me.
SPEAKER_04What whatever it is that you want to do, you know, not important to me. And some people some people are just plain stubborn. You know, it's an inconvenience. Uh uh, you know, uh it it cost can be a factor uh for a lot of people. Yeah. So so that becomes a big thing and has received much more attention in in uh in the last few years and certainly in a a number of the cardiologic uh guidelines.
SPEAKER_00Sure. So I want to touch on one more thing before we move on. Obviously, one of the one of the big parts of your not necessarily training, but maybe continuing education, uh just being a physician in general is attending meetings and conferences to stay up to date with what the latest happenings are in your field. And you know, one of the obviously one of the huge benefits of attending those kind of things is you have ac access to to experts.
SPEAKER_01That's right.
SPEAKER_00So you know if you could elaborate on that a little bit and kind of the the value that played in your story.
SPEAKER_04Well, well that's That's one of the one of the one of the advantages that I see that I feel fortunate to have, really. I feel fortunate to have in terms of my diagnosis is to have access to to some of the experts uh uh uh in amyloidosis. So um uh uh I have spoken uh with uh so my my doctor is at uh Beth Israel. There is a small cohort of patients.
SPEAKER_04I I shouldn't say small, I don't know what's you know, uh it depends on how you define small, but it's a cohort of patients of perhaps a hundred or so uh at Beth Israel that uh that uh uh uh uh Dr. uh Pablo Contero uh uh uh oversees uh that that that uh program. Um but I'm uh uh I was in contact with uh Dr. uh Rick Ruberg at Boston University's amyloidosis center.
SPEAKER_04Uh large amyloidosis center. Um uh uh he happens to be, he happens to be uh a friend of my stepson, but you know, that's beside the point. So I've spoken with Rick and I'm able to ask Rick, you know, what should I, you know, should I do something different? Should I take this or that or the other thing? Um uh I I've been at the meeting uh when when the idea of uh taking a drug like Jardiance uh uh was presented, you know, or was was talked about.
SPEAKER_04I went to one of the big meetings. Um I can't remember if it was the American Heart Association or the American College of Cardiology, but there was an amyloidosis session, so I went to the amyloidosis session. I directly asked Matt Maurer, who runs the amyloidosis center at Columbia what he thought of that.
unknownYeah.
SPEAKER_04I asked there there was uh another fellow whose name I've forgotten from Stanford. I asked him. Everybody gave me the same answer, so I take Jardians.
SPEAKER_00Yeah, it's definitely priceless to have access to uh some of the brightest minds in in this field. So, in contrast, the flip side of the coin now, how do you think being an amyloidosis patient impacted your cardiology practice? You know, did it have impacts on your relationships with your patients?
SPEAKER_04Uh not really. Uh well, not on my relationship with patients. I have had relationships with patients that stretch over 50 years. Uh I don't have too many patients who were still my patients in the beginning because you know, unfortunately, they've passed on. But um uh so I have these long-standing relationships and and uh the diagnosis of amyloidosis, you know, didn't didn't change any of that.
SPEAKER_02Yeah.
SPEAKER_04Um uh one of the things it did do, however, was make me uh uh aware uh of uh considering the diagnosis in in my patients in whom it may not be so obvious.
SPEAKER_02Sure.
SPEAKER_04So uh if I had uh patients, for example, that had uh uh uh left ventricular hypertrophy of uh thick, thick left ventricular walls on on echocardiogram. Um uh I would think, well, could this be amyloid? Uh so I would do uh serum protein electrophoresis and uh you know thinking about some of the other characteristics of the patient, um, you know, age, uh sex, uh wild type ATTR uh amyloid is a disease of old white men.
SPEAKER_04Uh so I have a lot of patients who fall into that fall into that category. So, you know, a 70-year-old or or uh 75-year-old with uh left ventricular hypertrophy like this who did not have terrible hypertension, I would think, you know, should we do the do you know do the testing? And so so I went about testing, you know, ordering serum protein electrophoreses and uh pyrophosphate scans.
SPEAKER_04And a number of them were negative, but uh there were several that were positive.
SPEAKER_02Yeah.
SPEAKER_00So if you put your patient hat on, what would you recommend or suggest physicians should know, or if there's anything they should do when they're dealing with patients that are diagnosed with a rare or complicated disease?
SPEAKER_04Um well, uh in the first place, uh, I go back to uh what uh Sir William Osler said in 1905. He said, listen to the patient. He is telling you the diagnosis. In those days, the only way to make a diagnosis was to talk to people because there were no tests. Sure. Okay. Today that has a different meaning for all of us. But but listen to the patient, you know, uh uh find out what bothers them uh and then try to uh uh think about the uh red flags and consider uh amyloidosis at an earlier stage uh of uh patients um uh uh course.
SPEAKER_04Uh uh I'll give you just an uh a little ex a little aside example of that.
SPEAKER_03A friend of ours, a woman who was in her I don't know call it she called it she must be in her early 70s.
SPEAKER_04Has has has uh uh had uh diarrhea and has been losing a lot of weight and she doesn't know why. I have no I don't take care of her. I don't know her doc I I mean I actually know her pastorenterologist at the at Beth Israel, but uh I don't know uh anything, you know, but I say, oh well, those might be symptoms of AL amyloidosis. Ask your doctor to do a seroprotadenal electrophoresis.
SPEAKER_04That's that's that's the that's the idea, trying to uh think about think about the diagnosis of amyloidosis. Um right? If you never you know, if you never think about it, you'll never make the diagnosis.
SPEAKER_00Absolutely. That's a great quote. And then what about for physicians after they've made the diagnosis? Is that they've identified amyloidosis, they're ready to diagnose their patient. Any words of wisdom for them in that setting or things that they should really be focusing on when they're having that discussion with their patients?
SPEAKER_04Uh it's important to um uh get people treated. So if if there are uh uh uh uh amyloidosis uh specialists or heart failure specialists uh or uh uh cardio oncologists or oncologists at your hospital, uh then perhaps a uh an appropriate referral uh should be done.
SPEAKER_04Um uh, you know, I I think there's uh a push to refer people to uh to the the you know some of the larger amyloidosis centers. But as we find more and more amyloidosis, I think we're gonna find more and more people treated outside of those centers. Uh you know, if you're uh uh I spoke spy I spoke with one fellow who uh lives in Montana. Uh uh well he was referred to Mayo Clinic.
SPEAKER_04See, his his the people at his his hospital were were were not uh you know were not an amyloidosis center, didn't have many patients in born uh uh you know really uh up to date on on what should be done. So he was referred to one of the amyloidosis centers. It's not necessary in in many places in the United States. Um if there's a if there's a question and if it can be done easily, then you should refer the patient to an amyloidosis center.
SPEAKER_04Another thing is to to try to help people to become advocates for yourself. We've been talking about that. Um and um uh people should know uh that they're not alone. That there are support groups, there are a number of nonprofit organizations uh and support groups like the amyloidosis support group that uh uh Muriel Finkel runs. Uh uh is very helpful to they they gather patients and and uh you know uh are very helpful in trying to uh uh enhance the experience uh of patients as they uh receive the diagnosis, as they take the treatment, as they live through the treatment and and carry, you know, and and try to carry on their lives.
SPEAKER_00So, how would you assess the level of knowledge in regards to amyloidosis that's amongst the cardiology community today? You know, have you seen changes in in I I'm not exactly sure how to put this, but maybe like the volume or kind of the attention that amyloidosis gets now in in the cardiology field compared to you know, say five, ten years ago?
SPEAKER_04Well, uh uh it's certainly increased. Uh I mean, I can't speak to the cardiology community, and I certainly can't speak to, you know, uh, you know, it let me let me put it put it this way. In Boston, we're fortunate because there are uh you know three major hospitals that are affiliated with Harvard. Uh uh one of which, uh the Brigham and Women's, uh has an amyloidosis center.
SPEAKER_04There's uh Boston Met Boston University, Boston Medical Center, uh, which is a university hospital, it has an amyloidosis center. There's Tufts uh University School of Medicine, uh, and uh, you know, and Beth Israel. So so we're fortunate to have many resources for people. Other other cities are not so fortunate. Uh uh you know, it's it depends, you know, and certainly the rural, the the more suburban, uh well, not not so much suburban, but in the rural areas, it's it's it's uh not not so easy.
SPEAKER_04Yeah just as an example, you can I can think of western Massachusetts.
SPEAKER_02Yeah.
SPEAKER_04You know, there are a number of you know, there's a hospital at Springfield, there's a hospital in uh in Pittsfield, but you know, not the same. Yeah. Uh so so uh uh I would I would advise people to to avail themselves of whatever uh uh resources uh they can you know they can reach.
SPEAKER_00So in closing, any comments for clinicians about their chances of seeing amyloidosis and how they can be sure that they think about and and keep amyloidosis on their differential.
SPEAKER_04Uh well I think uh someone said uh you may say not see it, but it sees you.
SPEAKER_02That's a great quote.
SPEAKER_04Uh I think it's going to be more and more common. I think as people realize uh two things. One one thing is uh to look for it in uh patients who have heart failure with preserved ejection fraction. Another one is to think of it in patients who are newly diagnosed as uh having hypertrophic uh cardiomyopathy, and you know, uh people uh well meaning older people, uh older people because it's a you know a certain percentage of those people are going to turn out to have amyloidosis, not hypertrophic cardiomyopathy.
SPEAKER_04Amyidosis as a separate section was added to the ACC AHA guidelines in 2022 for the first time. That's wonderful. So there's a there's a uh section in in those guy in those guidelines devoted uh um entirely to uh amyloidosis. So that's going to increase uh you know knowledge and awareness.
SPEAKER_04Uh the other thing is to be aware of the red flags. Uh somebody has carpal tunnel. Uh you know, the red flags for ATTR amyloidosis are carpal tunnel syndrome, um uh lumbar spinal stenosis, uh biceps tendon rupture, um, things like that. Uh some of the red flags for for uh uh AL amyloidosis uh are uh uh you know the nephrotic syndrome in people with heart failure, uh the uh uh and the pathic mnemonica, I think you don't see this this you don't see very often, uh but it was uh highlighted there.
SPEAKER_04It was an image in the New England Journal of Medicine about two weeks ago. Uh uh purple around the eyes and and what's called macroglossia, large tongue.
SPEAKER_02Yeah.
SPEAKER_04If you see anything like that, or you see biceps tendon uh rupture, think amyloidosis. And uh uh speaking of uh biceps tendon rupture, I once had a patient who had that. Interesting. That was that was she was she was he was he was the father of my office manager, talking about 40 years ago. Yeah, nobody knew anything about amyloidosis back then, and I have no idea if he had it or he didn't have it.
SPEAKER_00Certainly makes you wonder though.
SPEAKER_04He had coronary disease, however. Yeah. Um but I I thought that was such a strange thing. It it it stuck with me all these years. So looking for the red flags, uh thinking, considering the diagnosis, I think is important for physicians. Uh certainly from the patient's point of view, it's important because you come to the diagnosis, and there are treatments both for uh ATTR amyloidosis and for uh AL amyloidosis.
SPEAKER_04So, so whichever kind of amyloidosis you have or you turn out to have, uh, there's treatment for it. And uh we should all be aware of that and try to uh steer patients to places where they can get the appropriate treatment.
SPEAKER_00Well, Charles, it was an absolute pleasure to have you on with us today. And and thank you so much for sharing your journey as both a physician and an amyloidosis patient.
SPEAKER_04Thank you. It's a pleasure. It's a pleasure for me to try to help other people. One of the things in my retirement is that I'm trying to give back, so to speak, and uh uh try to help other people. And if I can I have a special interest in amyloidosis, as you can imagine. Slightly biased. And I'm I'm happy to try to help.
SPEAKER_00No, absolutely. I think there's a lot of really valuable messages for our audience in there, and as for our patient audience, you know, doctors that become patients experience emotions and and the same challenges that the rest of us do. So it was just a valuable thing to keep in the back of our minds. Thank you for listening to the All Things Amyloid Podcast. If you find our podcast informative, please follow and share it with others. If you want to learn more about the work we're doing at McKenzie's Mission, please visit mm713.org.
SPEAKER_00We'd also like to thank AstraZeneca Pharmaceuticals, Alexion Pharmaceuticals, Alnylan Pharmaceuticals, and Bridge Biopharma for their sponsorship to help raise awareness about amyloidosis. We hope you stay tuned for future episode drops. Thanks for listening.
Send us Fan Mail Adapted from his video, in this episode of All Things Amyloid, Dr. Mat Maurer, cardiologist at Columbia University Irving Medical Center discusses the importance of developing a broad differential in...
Send us Fan Mail It’s that time of year for Medicare Open Enrollment - a season that impacts so many of our amyloidosis patients. I’ll be speaking with Ann Kayrish, an expert in this area and someone who worked for...
Send us Fan Mail Caregiving seems to be a universal role that many of us play at some time in our lives, whether we are ready for it or not. It may be for a child, parent, spouse, family member, or friend who is facing...
Send us Fan Mail It’s that time of year for Medicare Open Enrollment - a season that impacts so many of our amyloidosis patients. I’ll be speaking with Ann Kayrish, an expert in this area and someone who worked for...
Send us Fan Mail Amyloidosis patients often experience GI issues, both before and after diagnosis. The commonness of these symptoms can increase the difficulty of diagnosing amyloidosis. Adapted from her video...